摘要
目的探究冠心病心肌缺血患者实施尼可地尔与卡维地洛联合治疗的效果。方法随机抽取2020年7月—2022年7月青岛市中心医院收治的76例冠心病心肌缺血患者,应用计算机完全随机分组法将患者分为试验组与参照组,每组38例。参照组行基础治疗方案,试验组加用尼可地尔联合卡维地洛治疗。比较两组的治疗效果、左室舒张功能、心绞痛改善情况、生命体征及不良反应。结果试验组治疗总有效率为94.74%,高于参照组的78.95%,差异有统计学意义(P<0.05)。两组治疗前左室舒张功能对比差异无统计学意义(P>0.05);治疗后试验组左室舒张功能中的左室舒张早期充盈峰(E峰)为(65.84±7.33)cm/s、左室舒张晚期充盈峰(A峰)为(60.36±8.46)cm/s,E/A为(1.12±0.19),均优于参照组的(59.98±8.04)cm/s、(65.24±9.35)cm/s、(0.93±0.20),差异有统计学意义(P<0.05)。两组治疗前心绞痛情况比较差异无统计学意义(P>0.05);治疗后试验组心绞痛发作频率(2.91±1.03)次/周、发作持续时间(2.43±0.88)min/次均低于参照组的(4.81±1.73)次/周、(5.42±1.04)min/周,差异有统计学意义(P<0.05)。两组治疗前生命体征水平对比差异无统计学意义(P>0.05);治疗后试验组心率(heart rate,HR)为(66.20±5.94)次/min,收缩压(systolic blood pressure,SBP)为(105.08±10.23)mmHg,舒张压(diastolic blood pressure,DBP)为(64.38±9.91)mmHg,均低于参照组的(72.53±6.18)次/min、(117.64±10.81)mmHg、(70.68±9.32)mmHg,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论冠心病心肌缺血患者实施尼可地尔联合卡维地洛治疗的效果较好,左室舒张功能、心绞痛情况及生命体征改善,不增加不良反应,安全性较好。
Objective To explore the effect of nicorandil combined with carvedilol in patients with ischemia of coronary heart disease myocardial.Methods A total of 76 patients with myocardial ischemia of coronary heart disease admitted to Qingdao Central Hospital from July 2020 to July 2022 were randomly selected,and the patients were divided into test group and reference group by computer complete randomization method,38 cases in each group.The reference group received basic treatment,and the test group received nicorandil combined with carvedilol.The treatment effects,left ventricular diastolic function,improvement of myocardial ischemia,vital signs and adverse effects were compared between the two groups.Results The total response rate in the test group was 94.74%,which was higher than 78.95%in the reference group,the difference was statistically significant(P<0.05).There was no significant difference in left ventricular diastolic function between the two groups before treatment(P>0.05);after treatment,the early left ventricular diastolic filling peak(peak E)of(65.84±7.33)cm/s,the late left ventricular diastolic filling peak(peak A)of(60.36±8.46)cm/s and E/A of(1.12±0.19)in the test group were better than(59.98±8.04)cm/s,(65.24±9.35)cm/s and(0.93±0.20)in the reference group,the differences were statistically significant(P<0.05).There was no significant difference in angina pectoris between the two groups before treatment(P>0.05);after treatment,the attack frequency and duration of test group were(2.91±1.03)times/week and(2.43±0.88)min/week,which were lower than those of(4.81±1.73)times/week and(5.42±1.04)min/week of reference group,the differences were statistically significant(P<0.05).There was no significant difference in the level of vital signs between the two groups(P>0.05);after treatment,heart rate(HR)was(66.20±5.94)times/min,systolic blood pressure(SBP)was(105.08±10.23)mmHg,diastolic blood pressure(DBP)was(64.38±9.91)mmHg,which were lower than(72.53±6.18)times/min,(117.64±10.81)mmHg,(70.68±9.32)mmHg in the reference group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse effects between the two groups(P>0.05).Conclusion The effect of nicorandil combined with carvedilol is better in patients with myocardial ischemia of coronary heart disease.The left ventricular diastolic function,angina pectoris and vital signs were improved,and without increasing adverse reactions.
作者
陈正迪
张林
CHEN Zhengdi;ZHANG Lin(Department of Cardiology,Qingdao Central Hospital,Qingdao Shandong 266042,China;Library,Qingdao Central Hospital,Qingdao Shandong 266042,China)
出处
《中国卫生标准管理》
2023年第12期130-134,共5页
China Health Standard Management
关键词
尼可地尔
卡维地洛
冠心病
心肌缺血
治疗效果
左室舒张功能
心绞痛改善情况
生命体征
nicorandil
carvedilol
coronary heart disease
myocardial ischemia
treatment effect
left ventricular diastolic function
improvement of angina pectoris
vital signs
